Gilead Says Early Results of Coronavirus Drug Trial Show Improvement With Shorter Remdesivir Treatment
04/29/2020
Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks, according to a CNBC report.
The company also said another trial by the National Institute of Allergy and Infectious Diseases met its main goal. It did not provide further details, however.
The clinical trial involved 397 patients with severe cases of Covid-19. The severe study is “single-arm,” meaning it did not evaluate the antiviral drug against a control group of patients who didn’t receive the drug.